International Journal of Infectious Diseases
Volume 14, Issue 2 , Pages e132-e140 , February 2010

Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG)

  • Ewa Lech-Maranda

      Affiliations

    • Department of Hematology, Medical University of Lodz, Copernicus Hospital, Ciolkowskiego 2 str, 93-510 Lodz, Poland
    • ,
  • Marek Seweryn

      Affiliations

    • Department of Hematology and BMT, Silesian Medical University, Katowice, Poland
    • ,
  • Sebastian Giebel

      Affiliations

    • Department of Hematology and BMT, Silesian Medical University, Katowice, Poland
    • ,
  • Jerzy Holowiecki

      Affiliations

    • Department of Hematology and BMT, Silesian Medical University, Katowice, Poland
    • ,
  • Beata Piatkowska-Jakubas

      Affiliations

    • Department of Hematology, Jagiellonian University, Cracow, Poland
    • ,
  • Joanna Wegrzyn

      Affiliations

    • Department of Hematology, Jagiellonian University, Cracow, Poland
    • ,
  • Aleksander Skotnicki

      Affiliations

    • Department of Hematology, Jagiellonian University, Cracow, Poland
    • ,
  • Marek Kielbinski

      Affiliations

    • Department of Hematology, Wroclaw Medical Academy, Poland
    • ,
  • Kazimierz Kuliczkowski

      Affiliations

    • Department of Hematology, Wroclaw Medical Academy, Poland
    • ,
  • Monika Paluszewska

      Affiliations

    • Department of Hematology and Oncology, Medical University of Warsaw, Poland
    • ,
  • Wieslaw Wiktor Jedrzejczak

      Affiliations

    • Department of Hematology and Oncology, Medical University of Warsaw, Poland
    • ,
  • Magdalena Dutka

      Affiliations

    • Department of Hematology, Medical University of Gdansk, Poland
    • ,
  • Andrzej Hellmann

      Affiliations

    • Department of Hematology, Medical University of Gdansk, Poland
    • ,
  • Marcin Flont

      Affiliations

    • Department of Hematology, Pomeranian Medical University, Szczecin, Poland
    • ,
  • Barbara Zdziarska

      Affiliations

    • Department of Hematology, Pomeranian Medical University, Szczecin, Poland
    • ,
  • Grazyna Palynyczko

      Affiliations

    • Department of Internal Medicine and Hematology, Institute of Hematology, Warsaw, Poland
    • ,
  • Lech Konopka

      Affiliations

    • Department of Internal Medicine and Hematology, Institute of Hematology, Warsaw, Poland
    • ,
  • Tomasz Szpila

      Affiliations

    • Department of Hematology, Institute of Hematology, Warsaw, Poland
    • ,
  • Krzysztof Gawronski

      Affiliations

    • Department of Clinical Hematology, Military Medical Academy, Warsaw, Poland
    • ,
  • Kazimierz Sulek

      Affiliations

    • Department of Clinical Hematology, Military Medical Academy, Warsaw, Poland
    • ,
  • Jaroslaw Sokolowski

      Affiliations

    • Department of Hematology, Bialystok Medical Academy, Poland
    • ,
  • Janusz Kloczko

      Affiliations

    • Department of Hematology, Bialystok Medical Academy, Poland
    • ,
  • Krzysztof Warzocha

      Affiliations

    • Department of Hematology, Institute of Hematology, Warsaw, Poland
    • ,
  • Tadeusz Robak

      Affiliations

    • Department of Hematology, Medical University of Lodz, Copernicus Hospital, Ciolkowskiego 2 str, 93-510 Lodz, Poland
    • Corresponding Author InformationCorresponding author. Tel.: +48 42 6895191; fax: +48 42 6895192.

Received 14 February 2008 ,Revised 22 September 2008 ,Accepted 4 February 2009.

References 

  1. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–3051
  2. Giamarellou H, Antoniadou A. Infectious complications of febrile leukopenia. Infect Dis Clin North Am. 2001;15:457–482
  3. Del Giudice I, Foa R. New therapies in onco-hematology and new infectious risk factors. Rev Clin Exp Hematol. 2005;9:E1
  4. Ray-Coquard I, Borg C, Bachelot T, Fayette J, Zufferey L, Guastalla JP, et al. Prognostic factors for febrile neutropenia. Bull Cancer. 2006;93:501–506
  5. Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982;60:454–462
  6. Wiernik PH, Banks PL, Case DC, Arlin ZA, Periman PO, Todd MB, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79:313–319
  7. Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, Hellmann A, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia. 2004;18:989–997
  8. Kantarjian HM, Estey EH, Keating MA. New chemotherapeutic agents in acute myeloid leukemia. Leukemia. 1996;10(Suppl 1):S4–6
  9. Robak T. Purine nucleoside analogues in the treatment of myeloid leukemias. Leuk Lymphoma. 2003;44:391–409
  10. Santana VM, Mirro J, Kearns C, Schell MJ, Crom W, Blakley RL. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol. 1992;10:364–370
  11. Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/− cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996;10:1563–1569
  12. Wrzesień-Kuś A, Robak T, Wierzbowska A, Lech-Marańda E, Pluta A, Wawrzyniak E, et al. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Ann Hematol. 2005;84:557–564
  13. Wrzesień-Kuś A, Robak T, Lech-Marańda E, Wierzbowska A, Dmoszyńska A, Kowal M, et al. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2- chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia—a report of the Polish Adult Leukemia Group (PALG). Eur J Haematol. 2003;71:155–162
  14. Cheson BD. New antimetabolites in the treatment of human malignancies. Semin Oncol. 1992;19:695–706
  15. Robak T, Korycka A, Kasznicki M, Wrzesien-Kus A, Smolewski P. Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. Curr Cancer Drug Targets. 2005;5:421–444
  16. Robak T, Lech-Maranda E, Korycka A, Robak E. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem. 2006;13:3165–3189
  17. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol. 1995;13:2431–2448
  18. Samonis G, Kontoyiannis DP. Infectious complications of purine analog therapy. Curr Opin Infect Dis. 2001;14:409–413
  19. Anaissie EJ, Kontoyiannis DP, O’Brien S, Kantarjian H, Robertson L, Lerner S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998;129:559–566
  20. Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, et al. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol. 2001;19:3611–3621
  21. Van Den Neste E, Michaux L, Layios N, Costantini S, Francart J, Lambert C, et al. High incidence of complications after 2-chloro-2′-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies. Ann Hematol. 2004;83:356–363
  22. Tam CS, Wolf MM, Januszewicz EH, Grigg AP, Prince HM, Westerman D, et al. A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies. Cancer. 2004;101:2042–2049
  23. Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, et al. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica. 1996;81:513–520
  24. Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A, et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol. 1998;58:105–109
  25. Huhmann IM, Watzke HH, Geissler K, Gisslinger H, Jäger U, Knöbl P, et al. FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol. 1996;73:265–271
  26. Vidarsson B, Abonour R, Williams EC, Woodson RD, Turman NJ, Kim K, et al. Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia. Leuk Lymphoma. 2001;41:321–331
  27. Carella AM, Cascavilla N, Greco MM, Melillo L, Sajeva MR, Ladogana S, et al. Treatment of ‘poor risk’ acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study. Leuk Lymphoma. 2001;40:295–303
  28. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis. 1997;25:551–573
  29. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–751
  30. Whimbey E, Kiehn TE, Brannon P, Blevins A, Armstrong D. Bacteremia and fungemia in patients with neoplastic disease. Am J Med. 1987;82:723–730
  31. Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcome of bacteremia in patients with cancer and neutropenia: observation from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997;25:247–259
  32. Mermel LA, Farr BM, Sherertz RJ, Raad II, O’Grady N, Harris JS, et al. Guidelines for management of intravascular catheter-related infection. Clin Infect Dis. 2001;32:1249–1272
  33. Madani TA. Clinical infections and bloodstream isolates associated with fever in patients undergoing chemotherapy for acute myeloid leukemia. Infection. 2000;28:367–373
  34. Juliusson G, Hoglund M, Karisson K, Lofgren C, Mollgard L, Paul C, et al. Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukemia when combined with cladribine. A randomized population-based phase II study. Br J Haematol. 2003;123:810–818
  35. Faderl S, Gandhi V, O’Brien S, Bonate P, Cortes J, Estey E, et al. Results of a phase I–II study of clofarabine in combination with cytarabine (Ara-C) in relapsed and refractory acute leukemias. Blood. 2005;105:940–947
  36. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol. 2000;110:273–284
  37. Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30(Suppl 1):S51–S59
  38. Kanamaru A, Tatsumi Y. Microbiological data for patients with febrile neutropenia. Clin Infect Dis. 2004;39(Suppl 1):S7–10
  39. Rolston KV. Challenges in the treatment of infections caused by Gram-positive and Gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis. 2005;40(Suppl 4):S246–S252

☆ This study was presented in part at the 12th Congress of the European Hematology Association, Vienna, Austria, June 7–10, 2007.

PII: S1201-9712(09)00193-3

doi: 10.1016/j.ijid.2009.02.021

International Journal of Infectious Diseases
Volume 14, Issue 2 , Pages e132-e140 , February 2010

Article Tools